Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial by Grimm, Richard et al.
© 2010 Grimm et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management
Vascular Health and Risk Management 2010:6 261–271 261
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R i G i n A L   R e s e A R c H
simultaneous treatment to attain blood pressure 
and lipid goals and reduced cV risk burden using 
amlodipine/atorvastatin single-pill therapy in 
treated hypertensive participants in a randomized 
controlled trial
Richard Grimm1 
Mobin Malik1 
carla Yunis2 
santosh sutradhar2 
Attila Kursun2
on behalf of the 
TOGeTHeR investigators
1Berman center for Outcomes 
and clinical Research, University 
of Minnesota, Minneapolis, Mn, UsA; 
2Pfizer inc, new York, nY, USA
correspondence: Richard H Grimm  
Berman center for Outcomes and 
clinical Research, 825 s. eighth st., ste 
440, Minneapolis, Mn 55404, Minneapolis 
Medical Research Foundation, Division 
of clinical epidemiology, Department 
of Medicine, Hennepin county Medical 
center, 701 Park Avenue south, 
Minneapolis, Mn 55415, UsA 
Tel +1 612 347 7755 
Fax +1 612 347 7761 
email grimm001@umn.edu
Abstract: TOGETHER investigated whether targeting multiple cardiovascular (CV) risk factors 
using single-pill amlodipine/atorvastatin (AML/ATO) and therapeutic lifestyle changes (TLC) 
results in greater blood pressure (BP)/lipid control and additional reduction in estimated cardio-
vascular disease (CVD) risk compared with blood pressure intervention only using amlodipine 
(AML) + TLC. TOGETHER was a 6-week, randomized, double-blind, double-dummy trial using 
hypertensive participants with additional CV risk factors without CVD/diabetes. Participants 
were randomized to either AML/ATO (5 to 10/20 mg) + TLC or AML (5 to 10 mg) + TLC. 
The primary end point was the difference in proportion of participants attaining both BP 
(140/90 mm Hg) and low-density lipoprotein cholesterol (LDL-C) (100 mg/dL) goals at 
week 6. At week 6, 67.8% of participants receiving AML/ATO + TLC attained the combined 
BP/LDL-C goal versus 9.6% with AML + TLC (RD [A–B]: 58.2; 95% CI [48.1 to 68.4] 
P  0.001; OR: 19.0; 95% CI 9.1 to 39.6; P  0.001). Significant reductions from baseline in 
LDL-C, total cholesterol and triglycerides and estimated 10-year Framingham risk were also 
observed. Treatment with AML/ATO was well tolerated. In conclusion, a multifactorial CV 
management approach is more effective in achieving combined BP/LDL-C targets as well as CV 
risk reduction compared with BP intervention only in this patient population.
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Introduction
Approximately one in three Americans are affected by cardiovascular disease (CVD).1 
Hypertension is an important modifiable cardiovascular (CV) risk factor that com-
monly clusters with other CV risk factors, such as dyslipidemia, smoking, and diabetes. 
These risk factors independently add to the overall risk of CV events.2 Although 
patients with hypertension and additional CV risk factors could potentially benefit 
significantly from the treatment of their absolute CV risk,3 the dominant paradigm in 
routine clinical practice is often focusing on each risk factor in isolation rather than 
simultaneously. There are many reasons for this isolated approach, both historical and 
practical, eg, current CV risk factor guidelines which traditionally have been focused on 
individual risk factors rather than taking an integrated approach addressing a patient’s 
absolute CV risk; and concern about pill burden by physicians and patients.4,5
Concern about an increasing pill burden may also negatively affect adher-
ence to co-administered antihypertensive and lipid-lowering medication;6 in turn, Vascular Health and Risk Management 2010:6 262
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improved adherence to co-administered antihypertensive 
and lipid-lowering therapy at levels seen in clinical trials may 
result in incremental cost savings compared with ‘real-world’ 
adherence levels.7 By reducing pill burden, combination pills 
containing both an antihypertensive and a lipid-lowering 
agent may therefore improve the management of CV risk and 
improve the cost-effectiveness of the dual therapy.
Therapeutic lifestyle changes (TLC) are an integral part 
of current hypertension guidelines.4 For patients at low to 
moderate CV risk, they recommend the use of pharmaco-
therapy if patients do not attain their blood pressure (BP) 
therapeutic goals through TLC alone.4
The aim of this randomized, double-blind, double-
dummy, controlled trial was to investigate whether a 
multiple risk factor management strategy using AML/ATO 
single-pill therapy + TLC results in greater BP/lipid control 
than the traditional approach of BP intervention only using 
amlodipine + TLC, in patients at low-to-moderate CV risk 
who would not be identified as candidates for statin therapy 
by current guidelines.
Methods
study participants
Participants who were enrolled in the trial were 21 years 
of age, had hypertension, but no history of CVD or diabetes, 
and had 2 of the following CV risk factors: age 45 years 
if male; 55 years if female; current smoker; a family 
history of premature coronary heart disease (CHD) in a 
first-degree relative; high-density lipoprotein cholesterol 
(HDL-C)  40 mg/dL (1.0 mmol/L); or a waist circumfer-
ence of 102 cm (40 inches) if male or 88 cm (35 inches) 
if female. All participants were previously treated with 
AML 5 mg, with BP either controlled or stage 1 hyper-
tension (systolic BP [SBP]  159 mm Hg and diastolic 
BP [DBP]  99 mm Hg) or controlled BP at 10 mg of 
amlodipine, in addition to a fasting low-density lipoprotein 
cholesterol (LDL-C) level at screening of 100 mg/dL 
and 170 mg/dL. Participants were excluded if they had a 
history of CHD, stroke, pulmonary vascular disease, or any 
of the following medications 14 days prior to screening: 
lipid-lowering drugs; calcium channel blockers other than 
AML; or 3 antihypertensive agents (including AML).
Trial design
TOGETHER was a 6-week, prospective, randomized, double-
blind, double-dummy clinical trial conducted between 
January 15, 2007 and April 18, 2008 within 38 US clinical 
sites. Following screening, eligible participants were 
randomized to either AML (5 to 10 mg) + TLC or AML/ATO 
single-pill therapy (5 to 10 mg/20 mg) + TLC (Figure 1). 
For operational reasons, participants in both treatment arms 
received a placebo: an amlodipine placebo in the amlodipine/
atorvastatin single-pill therapy arm, and an amlodipine/
atorvastatin single-pill placebo in the amlodipine arm.
Double-blinding occurred using a central web/telephone 
computer-based telerandomization system which dispensed 
two double-blind labeled bottles to participants at each 
dispensing visit (week 0 and week 4). Participants were 
instructed to take one tablet from each bottle per day at the 
same time daily. Randomized participants were stratified 
based on prior amlodipine dose and BP control, and those 
who were uncontrolled at 5 mg were uptitrated to 10 mg 
after randomization.
Blood pressure was measured using a digital blood pres-
sure monitor at each visit. Following a seated resting period 
(10 to 30 min), three seated BP measurements were taken 
and the mean of these measurements was calculated.
Serum lipid profiles (LDL-C, total cholesterol, triglycer-
ides, and HDL-C) were determined at each visit. Participants 
were required to fast for 10 hours prior to the blood test, and 
were asked not to perform any vigorous exercise the day 
before the test.
Participants in each treatment arm were counseled on 
implementing TLC as outlined by the American Heart 
Association’s Diet, Exercise and Smoking Cessation guide-
lines8 at the start of the study for use throughout the entire 
duration of the trial.
Efficacy measures
The primary end point in this study was the proportion of par-
ticipants attaining a combined BP goal of 140/90 mm Hg 
as defined by the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure (JNC 7)4 and an optimal LDL-C level 
(100 mg/dL) as defined by the National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP ATP III),9 
at week 6. The optimal LDL-C threshold of 100 mg/dL is 
a considerably more aggressive goal than the level recom-
mended by NCEP ATP III for most patients in this study 
population.
Secondary end points in this study included the proportion 
of participants attaining a combined BP goal of 140/90 mm 
Hg and an LDL-C goal of 100 mg/dL at week 4; the propor-
tion of participants attaining the LDL-C goal of 100 mg/dL 
at weeks 4 and 6; the proportion of participants attaining 
the BP goal of 140/90 mm Hg at weeks 4 and 6; change Vascular Health and Risk Management 2010:6 263
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from baseline in SBP, DBP, LDL-C, total cholesterol (TC), 
triglycerides, and HDL-C at weeks 4 and 6; the predicted 
10-year Framingham risk of CHD outcomes10 at weeks 4 
and 6; and the safety profile of the AML/ATO single-pill 
regimen + TLC compared with the AML + TLC regimen. 
The efficacy population was defined as all randomized par-
ticipants who took at least one dose of study drug and for 
whom at least one post-baseline efficacy measurement was 
available. The safety population was defined as all random-
ized participants who took at least one dose of study drug.
Adverse events
Adverse events (AEs) were monitored and recorded by the 
investigator from the time participants took at least one dose 
of study medication until the end of the treatment period. 
AEs were summarized by treatment group and severity, and 
encoded to a system organ class according to the Medical 
Dictionary for Regulatory Affairs (MedDRA), version 11.0. 
The investigator also assessed the causal relationship of the 
AE to the study medication. For any AE considered related 
to the study medication, follow-up by the investigator was 
required until the AE ceased or stabilized to levels deemed 
acceptable by the investigator.
statistical analysis
Originally, 260 participants were estimated to be required 
for randomization, assuming a response rate of 35% for the 
primary efficacy measure in the AML/ATO + TLC arm, 15% 
in the AML + TLC arm, and a discontinuation rate of no 
more than 5%, at a significance level of 5% to provide 90% 
power. The number of randomized participants (n = 245) was 
considered sufficient, based on the actual treatment effect 
from a trial with a similar population and design.11
An intent-to-treat (ITT) analysis was conducted includ-
ing participants who discontinued from the trial during the 
treatment period. Last observations from the non-completers 
were carried forward for final analysis. One participant ran-
domized to AML + TLC did not take any study drug and no 
data were available for this individual beyond the baseline 
visit. This patient was excluded from any analyses.
AML/ATO (5–10/20 mg) + TLC 
n = 122 
Group A  
Controlled BP, AML 5 mg 
n = 126 
Completed 
n = 107 
Completed 
n = 111 
Screening
(Visit 1) 
Rand/
Week 0 
(Visit 2) 
Week 6 
(Visit 4) 
Week 4 
(Visit 3) 
Screened 
n = 479 
Randomized 
n = 245a 
Not meeting 
inclusion 
criteria: 234 
Group C 
Controlled BP, AML 10 mg 
n = 72 
Group B 
Uncontrolled BP, AML 5 mg 
n = 46 
AML (5–10 mg) + TLC 
n = 122 
Discontinuations 
(n = 15) 
Discontinuations 
(n = 11) 
Figure 1 Trial design and flow of participants through the trial.
Notes: aOne participant was randomized, but did not receive any study medication, and was excluded from all analyses. Group A, prior amlodipine 5 mg + controlled BP; 
Group B, prior amlodipine 5 mg + uncontrolled BP; Group c, prior amlodipine 10 mg + controlled BP.
Abbreviations:  AML, amlodipine;    ATO, atorvastatin;    TLc, therapeutic lifestyle changes.Vascular Health and Risk Management 2010:6 264
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For the primary end point analysis, odds ratios (OR), 95% 
confidence intervals (CI), and the corresponding P-values were 
calculated based on a Cochran-Mantel-Haenszel (CMH) test 
stratified by baseline amlodipine dose and BP control. For 
the mean change from baseline data, difference in least-square 
(LS) means, its 95% CI, and the corresponding P-values were 
based on an analysis of covariance (ANCOVA) model with 
terms for treatment group, randomization stratum, and baseline 
values as explanatory variables in the model.
Results
Baseline demographics
In total, 245 participants were randomized to the two treatment 
arms (Figure 1). However, one randomized participant in the 
AML + TLC arm did not take any study medication and was 
excluded from all analyses. Of the 244 participants who took 
study medication, n = 111 and n = 107 completed the trial in 
the AML + TLC and AML/ATO + TLC arms, respectively 
(Figure 1). The mean age of participants was 56 years (ranging 
from 24 to 84 years), with more than half of them being white 
(Table 1). There were no significant differences in BP, lipid, 
and 10-year Framingham CHD risk at baseline between par-
ticipants in the two treatment arms (Table 1).
BP and LDL-c goal attainment
The proportion of participants attaining combined SBP/
LDL-C goal at week 6 (ie, the primary end point) was 9.6% 
in the AML + TLC arm, and 67.8% in the AML/ATO + TLC 
arm (RD [A–B]: 58.2; 95% CI [48.1 to 68.4]; P  0.001; 
OR, 19.0; 95% CI [9.1 to 39.6]; P  0.001; Figure 2). This 
difference was already apparent at week 4, when 5.2% 
participants on the AML + TLC-based regimen attained 
the combined goal compared with 62.9% participants 
receiving AML/ATO single-pill therapy, along with TLC 
Table 1 Baseline demographic characteristicsa
AML + TLC (n = 122) AML/ATO + TLC (n = 122)  P-valuesb
Age, years, mean (range) 55.5 (33–80) 56.5 (24–84) 0.43
Race, n (%) 0.92
  White 62 (50.8) 63 (51.6) –
  Black 38 (31.1) 39 (32.0) –
  Asian 10 (8.2) 11 (9.0) –
  Other 12 (9.8) 9 (7.4) –
Gender, n (%) 0.25
  Male 66 (54.1) 57 (46.7) –
  Female 56 (45.9) 65 (53.3) –
smoking status, n (%) 0.44
  never smoked 55 (45.1) 65 (53.3) –
  ex-smoker 27 (22.1) 23 (18.9) –
  current smoker 40 (32.8) 34 (27.9) –
sBP,  mm Hg, mean (sD) 132.9 (12.3) 132.3 (11.3) 0.71
DBP,  mm Hg, mean (sD) 81.9 (8.2) 81.0 (9.5) 0.42
LDL-c, mg/dL, mean (sD) 131.5 (24.7) 127.4 (21.7) 0.17
Tc, mg/dL, mean (sD) 214.0 (30.7) 209.5 (29.7) 0.24
Triglycerides, mg/dL, mean (sD) 137.6 (80.9) 140.4 (99.5) 0.81
HDL-c, mg/dL, mean (sD) 55.5 (16.1) 54.7 (17.5) 0.74
10-year Framingham risk 
for cHD,10 mean (%)
8.5 (6.8) 8.3 (7.6) 0.77
stratum, n (%)
  Group A 63 (51.6) 63 (51.6) 0.99
  Group B 23 (18.9) 23 (18.9)
  Group c 36 (29.5) 36 (29.5)
Notes: aFor the safety population; bFor categorical variables calculated based on approximate chi-square test; for continuous variables based on a t-test.
Group   A, prior amlodipine 5 mg + controlled BP; Group B, prior amlodipine 5 mg + uncontrolled BP; Group c, prior amlodipine 10 mg + controlled BP.
Abbreviations: AML, amlodipine;   ATO, atorvastatin; TLc, therapeutic lifestyle changes; sD, standard deviation; BP, blood pressure; sBP, systolic BP; DBP, diastolic BP; 
LDL-c, low-density lipoprotein cholesterol;   Tc, total cholesterol; HDL-c, high-density lipoprotein cholesterol.Vascular Health and Risk Management 2010:6 265
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(RD [A–B]: 57.7; 95% CI [47.9 to 67.5]; P  0.001; OR, 
31.4; 95% CI [12.6 to 78.1]; P  0.001; Figure 2).
LDL-C goal was achieved by 7.0% in the AML + TLC 
arm at week 4 compared with 82.8% participants in the 
AML/ATO + TLC arm (RD [A–B]: 75.8; 95% CI [67.4 
to 84.2]; P  0.001; OR 65.5; 95% CI [27.1 to 158.3]; 
P  0.001; Figure 3); at week 6, 11.3% in the AML + TLC 
arm were at LDL-C goal versus 83.9% participants on the 
single-pill combination along with TLC (RD [A–B]: 72.6; 
95% CI [63.7 to 81.5]; P  0.001; OR, 42.0; 95% CI [19.4 
to 91.0]; P  0.001; Figure 3). The difference in combined 
SBP/DBP goal attainment between the two treatment arms 
was not significant (Figure 4); however, a 3.3 mm Hg differ-
ence in LS means in SBP at week 6 between the two groups 
was observed (Table 2).
Mean changes from baseline in lipids, 
sBP/DBP, and 10-year Framingham risk
There were significant mean percentage reductions from base-
line in LDL-C, TC, and triglycerides in the AML/ATO + TLC 
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arm compared with the AML + TLC arm at weeks 4 and 
6 (Table 2). There was no difference in DBP between the 
two treatment groups and no difference in SBP at week 4. 
However, at week 6 the difference in LS means in SBP was 
3.3 mm Hg lower in the AML/ATO arm compared with the 
AML arm (P = 0.02; Table 2).
In the AML/ATO + TLC arm, the 10-year Framingham 
risk for CHD at baseline was 8.2% and was reduced to 5.5% 
and 5.4% at week 4 and week 6, respectively, compared with 
the AML + TLC arm in which the 10-year Framingham risk 
was 8.1% at baseline and remained unchanged at week 6. 
At week 4, the percentage relative reduction from baseline 
in 10-year Framingham risk for CHD in participants on 
AML/ATO + TLC was 39.6%, compared with a percentage 
relative increase of 0.6% in participants on AML + TLC. 
At week 6, the corresponding percentage relative reduc-
tion from baseline was 42.0% in the AML/ATO + TLC arm 
compared with a percentage relative increase of 4.5% in the 
AML + TLC arm (Table 2).
safety and tolerability
Of the 244 participants who were included in the safety 
analysis, 4 discontinued from the trial due to an adverse event 
or laboratory abnormality, all of which in the AML/ATO + 
TLC arm (Table 3). Of these, 3 participants had AEs which 
were considered related to study medication: one discontinued 
due to mild abdominal pain, one due to severe tinnitus, and a 
third due to moderate abdominal pain and joint sprain.
There were no deaths or serious AEs reported during the 
conduct of the trial. Overall, treatment-related AEs occurred 
in 18 (14.8%) and 11 (9.0%) of participants in the AML + 
TLC and AML/ATO + TLC treatment arms, respectively. 
The majority of events in both arms were mild. Changes in 
liver function test and creatine phosphokinase were mild to 
moderate and similar in incidence and severity with previous 
reports and known profile of the study medication.
Discussion
In clinical practice, patients with hypertension and addi-
tional CV risk factors are usually treated in isolation, ie, by 
initially focusing on treating their BP, and treating another 
CV risk factor only after the patient’s BP has been controlled, 
thereby leaving the patient exposed to considerable residual 
CV risk in the interim. These results show that simultaneous 
treatment of BP and lipids using AML/ATO single-pill 
therapy, along with TLC, provides significant and rapid 
benefits for helping patients attain their combined BP and 
lipid goals, with a greater reduction in absolute 10-year 
Framingham risk for CHD outcomes, compared with an 
approach based on current guideline recommendations4 
using AML + TLC only.
As expected, significant improvements were observed 
in attaining LDL-C goals (100 mg/dL). In fact, in this 
population LDL-C, not BP, was the driving factor behind 
the significant benefits that were observed for combined 
BP/LDL-C goal attainment, presumably as participants 
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Table 3 Treatment-emergent all-causality adverse events by system organ class
All-causality
AML + TLC 
n = 122, n (%)
AML/ATO + TLC  
n = 122, n (%)
With adverse events 37 (30.3) 34 (27.9)
Discontinued due to adverse events/laboratory 
abnormalities
0 (0.0) 4 (3.3)
System organ class
Blood and lymphatic system disorders 0 (0.0) 1 (0.8)
cardiac disorders 0 (0.0) 1 (0.8)
ear and labyrinth disorders 2 (1.6) 1 (0.8)
eye disorders 2 (1.6) 0 (0.0)
Gastrointestinal disorders 1 (0.8) 6 (4.9)
General disorders and administration site 
conditions
9 (7.4) 5 (4.1)
Hepatobiliary disorders 0 (0.0) 1 (0.8)
immune system disorders 0 (0.0) 1 (0.8)
infections and infestations 9 (7.4) 7 (5.7)
injury, poisoning, and procedural complications 0 (0.0) 1 (0.8)
investigations 6 (4.9) 3 (2.5)
Metabolism and nutritional disorders 1 (0.8) 0 (0.0)
Musckuloskeletal and connective tissue disorders 6 (4.9) 7 (5.7)
nervous system disorders 1 (0.8) 5 (4.1)
Psychiatric disorders 1 (0.8) 2 (1.6)
Renal and urinary disorders 2 (1.6) 0 (0.0)
Respiratory, thoracic and mediastinal disorders 1 (0.8) 1 (0.8)
skin and subcutaneous disorders 2 (1.6) 2 (1.6)
Vascular disorders 7 (5.7) 3 (2.5)
Abbreviations: AML, amlodipine;   ATO, atorvastatin;   TLc, therapeutic lifestyle changes; BP, blood pressure.
were already receiving amlodipine prior to the trial, and 
consequently any additional improvements in BP goal attain-
ment by the single-pill combination were minor, since BP 
treatment was equally optimized between the two arms (data 
not shown). The LDL-C threshold of 100 mg/dL is a con-
siderably more aggressive goal than the one recommended 
by NCEP ATP III for most patients in this population. The 
decision to implement the LDL-C goal of 100 mg/dL for 
every patient in this population was made for operational 
reasons, as it is not possible to preserve the blind with indi-
vidually determined therapeutic goals.
The effect of the atorvastatin component of the single-pill 
combination on LDL-C is also most likely the driving force 
behind the 2.8% percentage point drop in LS means in the 
10-year Framingham risk for CHD events within 6 weeks 
seen in this trial. There was no percentage reduction in LS 
means in the 10-year Framingham risk in the AML + TLC 
arm, presumably because patients had been previously treated 
with amlodipine, as stated above. This demonstrates that a 
simultaneous treatment approach using single-pill AML/ATO 
reduces CV risk burden in this population compared with 
BP intervention only.
Although the difference in combined SBP/DBP goal attain-
ment between the two treatment arms was not statistically 
significant in this study, a 4 mm Hg difference in SBP at 
week 6 was nevertheless observed, despite equal mean doses 
of amlodipine at week 6 in both treatment arms (data not 
shown). This may be due to a modest BP-lowering effect of 
the atorvastatin component of the single-pill combination 
which has previously been reported for statins.12,13
The participants in the TOGETHER trial consisted of 
previously treated hypertensive individuals with additional 
CV risk factors but conventionally normal lipid levels (fasting 
LDL-C: 170 mg/dL [4.4 mmol/L]), in which a statin 
(in the form of the atorvastatin component in the single-pill 
AML/ATO study medication) in addition to AML + TLC Vascular Health and Risk Management 2010:6 270
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resulted in improved combined BP/LDL-C goals compared 
with individuals on AML + TLC alone. Cholesterol lower-
ing in addition to an antihypertensive regimen has been 
shown to translate into reduced CHD outcomes in a hyper-
tensive population with normal lipid levels (nonfasting 
TC  251.4 mg/dL [6.5 mmol/L]) in the lipid-lowering arm 
of the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid 
Lowering Arm (ASCOT-LLA),14 indicating that a simulta-
neous multiple risk factor management strategy results in 
improved CHD outcomes.
The efficacy and safety of AML/ATO single-pill therapy 
has been demonstrated in another randomized trial, the 
Caduet in Untreated Subjects Population (CUSP) trial.11 
The CUSP results are highly consistent with our results. In 
CUSP, similar to TOGETHER, a significant difference in 
combined BP (140/90 mm Hg)/LDL-C (100 mg/dL) goal 
attainment was reported between a treatment arm receiving 
AML/ATO + TLC versus a control arm (AML/ATO + TLC, 
47.6% versus placebo + TLC, 1.7%; P  0.001) within a 
short period of time (4 weeks in CUSP versus 6 weeks in 
TOGETHER).11 This suggests that AML/ATO single-pill 
therapy, in addition to TLC, provides CV benefits in both 
treated and untreated hypertensive individuals within a short 
period of time.
The results from the TOGETHER trial show that the ini-
tiation of a multiple risk factor management strategy using 
AML/ATO single-pill therapy + TLC leads to improvements 
in CV risk burden compared with an approach using an 
AML + TLC-based regimen alone based on current guide-
line recommendations, in patients previously treated with 
amlodipine.
Conclusions
AML/ATO single-pill therapy + TLC is more effective in 
achieving combined BP/LDL-C therapeutic targets than an 
AML + TLC-based regimen based on current guidelines in 
treated hypertensive patients with additional CV risk factors, 
highlighting the utility of a simultaneous treatment approach 
for the rapid reduction of CV risk burden. The single-pill 
combination was well tolerated in these patients, in line with 
previous reports.
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